Not sure why you think OIL is top heavy on the finance side. Bruce Andrews has been replaced by Michael Corry, Peter Delaney has been replaced by Archie Fraser and gone to where is best suited, product development. Andrew Froude has been appointed "General Manager - Preclinical Research Products as part of the company’s new take-to-market strategy for the 2nd generation CellLive2 Product."
In short there has been no addition on the finance side and other appointments go directly to marketing or customer/partner liaising not to mention better shareholder relations.
If you think the Board is overpaid go to page 25 of the prospectus and the figures are there. I can`t see too much waste there and if I was on the Board reading the crap that is posted here I would be thinking if saving OIL is worth the effort.
Why don`t you save your opinion/s till the new management have been given a little time to develop the OIL business and deliver on the potential.
Ann: Optiscan announces new General Manager appointment-OIL.AX, page-30
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $129.4M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 14.0¢ | $71.49K | 479.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 6886 | 1 |
View Market Depth
| Last trade - 12.32pm 04/12/2024 (20 minute delay) ? |
| OIL (ASX) Chart |
